Renal Cell Carcinoma – Landscape & Forecast – Disease Landscape & Forecast
The renal cell carcinoma market is witnessing a substantial change, largely fueled by label expansions of immune checkpoint inhibitor therapies. Combination regimens, including Opdivo plus Yervoy (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) plus Inlyta (Pfizer), are revolutionizing the treatment of advanced disease. The approval and uptake of Opdivo plus Cabometyx (Exelixis / Ipsen) and Keytruda plus Lenvima / Kisplyx (Eisai) will also drive fierce competition in this setting. Treatment choices for early-stage disease are also increasing with Keytruda’s label expansion as an adjuvant therapy. Moreover, the FDA’s approval of Welireg (Merck & Co.) will reshape the treatment of VHL-associated tumors. The anticipated entry of other agents such as bempegaldesleukin (Nektar Therapeutics) will further diversify treatment options during the forecast period and create a highly competitive and dynamic market.
Questions answered
- What is the size of the early-stage and advanced / metastatic drug-treatable renal cell carcinoma population, and how will drug-treatment rates change over time?
- What is the expected market impact of recent drug approvals and label expansions of novel combinations incorporating Opdivo, Cabometyx, Welireg, Lenvima / Kisplyx, and Keytruda for renal cell carcinoma?
- Which are the most promising emerging therapies in the late-phase pipeline, and how will they shape the future of the renal cell carcinoma market?
- What are the drivers and constraints in renal cell carcinoma, and how will the market evolve over the forecast period?
Product Description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution Enhancement
Disease Landscape & Forecast will feature continuous updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Table of contents
- Renal Cell Carcinoma - Landscape & Forecast - Disease Landscape & Forecast
- Key Updates
- Q2 2022
- April 2022
- Q1 2022
- March 2022
- February 2022
- January 2022
- Q4 2021
- December 2021
- November 2021
- October 2021
- Q3 2021
- September 2021
- August 2021
- Q2 2021
- May 2021
- April 2021
- Q2 2022
- Key Findings
- Market Outlook
- Key Findings
- Market Share of Drug Classes for Renal Cell Carcinoma: 2020
- Market Share of Drug Classes for Renal Cell Carcinoma: 2030
- Drug-Treatable Population Share and Major-Market Sales Share in Renal Cell Carcinoma: 2020
- Drug-Treatable Population Share and Major-Market Sales Share in Renal Cell Carcinoma: 2030
- Population Positioning of Current Therapies in Renal Cell Carcinoma
- Population Positioning of Emerging Therapies in Renal Cell Carcinoma
- Renal Cell Carcinoma SWOT Analysis
- Market Drivers and Constraints
- What Factors Are Driving the Market for Renal Cell Carcinoma?
- What Factors Are Constraining the Market for Renal Cell Carcinoma?
- Major-Market Sales for Renal Cell Carcinoma by Drug-Treatable Population, 2020-2030
- Major-Market Sales of Immune Oncology Therapies for Renal Cell Carcinoma, 2020-2030
- Major-Market Sales of Angiogenesis Inhibitors for Renal Cell Carcinoma, 2020-2030
- Segment-Specific Trends
- Patient-Share Dynamics of Therapies for Early-Stage (Stage I-III) Renal Cell Carcinoma, United States, 2020-2030
- Patient-Share Dynamics of Key Therapies in First-Line Advanced or Metastatic Renal Cell Carcinoma, United States, 2020-2030
- Patient-Share Dynamics of Key Therapies in First-Line Advanced or Metastatic Renal Cell Carcinoma, Japan, 2020-2030
- Patient-Share Dynamics of Key Therapies in Second-Line Advanced or Metastatic Renal Cell Carcinoma, United States, 2020-2030
- Patient-Share Dynamics of Key Therapies in Second-Line Advanced or Metastatic Renal Cell Carcinoma, Japan, 2020-2030
- Patient-Share Dynamics of Key Therapies in Third-Line Advanced or Metastatic Renal Cell Carcinoma, United States, 2020-2030
- Patient-Share Dynamics of Key Therapies in Third-Line Advanced or Metastatic Renal Cell Carcinoma, Japan, 2020-2030
- Patient-Share Dynamics of Key Therapies in Fourth-Line Advanced or Metastatic Renal Cell Carcinoma, United States, 2020-2030
- Patient-Share Dynamics of Key Therapies in Fourth-Line Advanced or Metastatic Renal Cell Carcinoma, Japan, 2020-2030
- Key Findings
- Forecast
- Market Forecast Assumptions
- Market Forecast Dashboard
- Etiology and Pathophysiology
- Disease Overview
- Progression of Renal Cell Carcinoma
- Anatomy and Histology of Renal Cell Carcinoma
- Prognostic Models for Renal Cell Carcinoma
- International Metastatic Renal Cell Carcinoma Database Consortium Risk Assessment System for Stage IV Renal Cell Carcinoma
- UCLA Integrated Staging System for Renal Cell Carcinoma
- Classification of Renal Cell Carcinoma
- Staging of Renal Cell Carcinoma
- TNM Staging System for Renal Cell Carcinoma
- Definitions of the TNM Staging System for Renal Cell Carcinoma
- Key Pathways and Drug Targets for Renal Cell Carcinoma
- Disease Overview
- Epidemiology
- Key Findings
- Key Updates
- Epidemiology Populations
- Disease Definition
- Methods
- Sources Used for Diagnosed Incidence of Renal Cell Carcinoma
- Diagnosed Incident Cases of Renal Cell Carcinoma: 2020-2030
- Disease Definition
- Methods
- Sources Used for Stage Distribution of Renal Cell Carcinoma
- Diagnosed Incident Cases of Renal Cell Carcinoma by Stage Distribution: 2020-2030
- Disease Definition
- Methods
- Sources Used for Recurrent Incidence of Renal Cell Carcinoma
- Recurrent Incident Cases of Renal Cell Carcinoma: 2020-2030
- Renal Cell Carcinoma Patient Flow
- Drug-Treatable Cases of Renal Cell Carcinoma: 2020-2030
- Drug-Treated Cases of Renal Cell Carcinoma: 2020-2030
- Key Findings
- Current Treatment
- Key Findings
- Treatment Goals
- Key Endpoints Used in Clinical Trials for Renal Cell Carcinoma
- Key Current Therapies
- Overview
- Mechanism of Action of Key Current Drug Classes Used for Renal Cell Carcinoma
- Current Treatments Used for Renal Cell Carcinoma
- Market Events Influencing the Use of Key Current Therapies in Renal Cell Carcinoma
- Key Results From Select Clinical Trials Investigating Opdivo for the Treatment of Renal Cell Carcinoma
- Ongoing Clinical Development of Opdivo
- Key Ongoing Clinical Trials of Opdivo in the Treatment of Renal Cell Carcinoma
- Expert Insight: Opdivo
- Key Results From Select Clinical Trials Investigating Opdivo and Yervoy Combination Therapy for the Treatment of Renal Cell Carcinoma
- Ongoing Clinical Development of Opdivo and Yervoy Combination Therapy
- Key Ongoing Clinical Trials of Opdivo and Yervoy Combination Therapy in the Treatment of Renal Cell Carcinoma
- Expert Insight: Opdivo and Yervoy Combination Therapy
- Key Results From Select Clinical Trials Investigating Keytruda for the Treatment of Renal Cell Carcinoma
- Ongoing Clinical Development of Keytruda
- Key Ongoing Clinical Trials of Keytruda in the Treatment of Renal Cell Carcinoma
- Expert Insight: Keytruda
- Key Results From Select Clinical Trials Investigating Bavencio for the Treatment of Renal Cell Carcinoma
- Ongoing Clinical Development of Bavencio
- Key Ongoing Clinical Trials of Bavencio in the Treatment of Renal Cell Carcinoma
- Expert Insight: Bavencio
- Key Results From Select Clinical Trials Investigating Sutent for the Treatment of Renal Cell Carcinoma
- Expert Insight: Sutent
- Key Results From Select Clinical Trials Investigating Votrient for the Treatment of Renal Cell Carcinoma
- Expert Insight: Votrient
- Advantages and Disadvantages of Nexavar
- Expert Insight: Nexavar
- Key Results From Select Clinical Trials Investigating Inlyta for the Treatment of Renal Cell Carcinoma
- Expert Insight: Inlyta
- Ongoing Clinical Development of Avastin
- Expert Insight: Avastin
- Key Results From Select Clinical Trials Investigating Cabometyx for the Treatment of Renal Cell Carcinoma
- Ongoing Clinical Development of Cabometyx
- Key Ongoing Clinical Trials of Cabometyx in the Treatment of Renal Cell Carcinoma
- Expert Insight: Cabometyx
- Key Results From Select Clinical Trials Investigating Lenvima / Kisplyx for the Treatment of Renal Cell Carcinoma
- Ongoing Clinical Development of Lenvima / Kisplyx
- Key Ongoing Clinical Trials of Lenvima / Kisplyx in the Treatment of Renal Cell Carcinoma
- Expert Insight: Lenvima / Kisplyx
- Key Results From Select Clinical Trials Investigating Fotivda for the Treatment of Renal Cell Carcinoma
- Ongoing Clinical Development of Fotivda
- Key Ongoing Clinical Trials of Fotivda in the Treatment of Renal Cell Carcinoma
- Expert Insight: Fotivda
- Advantages and Disadvantages of Torisel
- Expert Insight: Torisel
- Ongoing Clinical Development of Afinitor
- Key Ongoing Clinical Trials of Afinitor in the Treatment of Renal Cell Carcinoma
- Expert Insight: Afinitor
- Key Results From Select Clinical Trials Investigating Welireg for the Treatment of Renal Cell Carcinoma
- Ongoing Clinical Development of Welireg
- Key Ongoing Clinical Trials of Welireg in the Treatment of Renal Cell Carcinoma
- Expert Insight: Welireg
- Medical Practice
- Early-Stage Renal Cell Carcinoma: Stages I-III
- First-Line Advanced or Metastatic Renal Cell Carcinoma: Stage IV
- Second-Line Advanced or Metastatic Renal Cell Carcinoma
- Third- and Fourth-Line Advanced or Metastatic Renal Cell Carcinoma
- Patient Characteristics Influencing Drug Selection in Renal Cell Carcinoma
- Treatment Decision Tree for Renal Cell Carcinoma: United States
- Treatment Decision Tree for Renal Cell Carcinoma: EU5
- Treatment Decision Tree for Renal Cell Carcinoma: Japan
- Key Findings
- Unmet Need Overview
- Current and Future Attainment of Unmet Needs in Renal Cell Carcinoma
- Top Unmet Needs in Renal Cell Carcinoma: Current and Future Attainment
- Expert Insight: Unmet Need in Renal Cell Carcinoma
- Emerging Therapies
- Key Findings
- Key Emerging Therapies
- Key Therapies in Development for Renal Cell Carcinoma
- Estimated Market Authorization Dates of Key Emerging Therapies for the Treatment of Renal Cell Carcinoma
- Analysis of Clinical Development Program for Tecentriq
- Key Ongoing Clinical Trials of Tecentriq in the Treatment of Renal Cell Carcinoma
- Expert Insight: Tecentriq
- Key Results From Select Clinical Trials Investigating Imfinzi for the Treatment of Renal Cell Carcinoma
- Analysis of the Clinical Development Program for Imfinzi
- Key Ongoing Clinical Trials of Imfinzi in the Treatment of Renal Cell Carcinoma
- Expert Insight: Imfinzi
- Expectations for Market Authorization and Sales Opportunity of Imfinzi in Renal Cell Carcinoma
- Key Results From Select Clinical Trials Investigating Tremelimumab for the Treatment of Renal Cell Carcinoma
- Analysis of Clinical Development Program for Tremelimumab
- Key Ongoing Clinical Trials of Imfinzi in the Treatment of Renal Cell Carcinoma
- Expert Insight: Tremelimumab
- Expectations for Market Authorization and Sales Opportunity of Tremelimumab in Renal Cell Carcinoma
- Analysis of Clinical Development Program for Quavonlimab
- Key Ongoing Clinical Trials of Quavonlimab in the Treatment of Renal Cell Carcinoma
- Expert Insight: Quavonlimab
- Expectations for Market Authorization and Sales Opportunity of Quavonlimab in Renal Cell Carcinoma
- Key Results From Select Clinical Trials Investigating Orpathys for the Treatment of Renal Cell Carcinoma
- Analysis of Clinical Development Program for Orpathys
- Key Ongoing Clinical Trials of Orpathys in the Treatment of Renal Cell Carcinoma
- Expert Insight: Orpathys
- Expectations for Market Authorization and Sales Opportunity of Orpathys in Renal Cell Carcinoma
- Key Results From Select Clinical Trials Investigating Dovitinib for the Treatment of Renal Cell Carcinoma
- Analysis of Clinical Development Program for Dovitinib
- Expert Insight: Dovitinib
- Expectations for Market Authorization and Sales Opportunity of Dovitinib in Renal Cell Carcinoma
- Key Results From Select Clinical Trials Investigating Bempegaldesleukin for the Treatment of Renal Cell Carcinoma
- Analysis of the Clinical Development Program for Bempegaldesleukin
- Key Ongoing Clinical Trials of Bempegaldesleukin in the Treatment of Renal Cell Carcinoma
- Expert Insight: Bempegaldesleukin
- Expectations for Market Authorization and Sales Opportunity of Bempegaldesleukin in Renal Cell Carcinoma
- Key Results From Select Clinical Trials Investigating Abexinostat for the Treatment of Renal Cell Carcinoma
- Analysis of Clinical Development Program for Abexinostat
- Key Ongoing Clinical Trials of Abexinostat in the Treatment of Renal Cell Carcinoma
- Expert Insight: Abexinostat
- Expectations for Market Authorization and Sales Opportunity of Abexinostat in Renal Cell Carcinoma
- Early-Phase Pipeline Analysis
- Key Findings
- Access and Reimbursement Overview
- Region-Specific Reimbursement Practices
- Key Market Considerations in Renal Cell Carcinoma: United States
- General Reimbursement Environment: United States
- Key Market Access Considerations in Renal Cell Carcinoma: EU5
- General Reimbursement Environment: EU5
- Key Market Access Considerations in Renal Cell Carcinoma: Japan
- General Reimbursement Environment: Japan
- Region-Specific Reimbursement Practices
- Appendix
- Renal Cell Carcinoma Bibliography
- Key Updates
Kiran Bountra, M.Res., Ph.D., is a senior analyst on the Oncology team at Clarivate. He has a background in the biotechnology sector, specializing in target validation and small-molecule drug discovery. Before joining Clarivate, he worked as a senior scientist at OMass Therapeutics, with a focus on basal cell carcinoma and epilepsy programs. Previously, he trained as a structural biologist, researching the mechanisms of transport proteins involved in drug resistance. He holds a Ph.D. in biochemistry from Imperial College London.
Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. His areas of expertise are oncology and psychiatry. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.
Sorcha Cassidy, M.Res., Ph.D., is an associate director on the Oncology team at Clarivate. She manages a team of analysts who produce syndicated primary and secondary market research reports and custom analysis on a wide range of oncology indications. Dr. Cassidy also provides client support for all oncology products and has expertise in hematologic malignancies and CAR T-cell therapies. She has published oncology market assessment articles in Nature Reviews Drug Discovery. Previously, Dr. Cassidy was a market research manager at Janssen UK. She obtained her M.Res. and Ph.D. in immunology from Imperial College London, where she investigated the role of innate immune modulators (killer immunoglobulin-like receptors [KIRs]) on natural killer cells in various diseases.